Transgene Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec Oncolytic Immunotherapy in Advanced Liver Cancer
BusinessWire - Wed Jan 06, 1:00AM CST
Regulatory News:
Transgene Reports Third Quarter 2015 Financial Results
BusinessWire - Wed Oct 21, 10:45AM CDT
Regulatory News:
Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer
BusinessWire - Wed Aug 19, 10:45AM CDT
Regulatory News:
Transgene Reports First Quarter 2015 Financial Results
BusinessWire - Wed Apr 22, 11:00AM CDT
Regulatory News:
Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity
ACCESSWIRE - Thu Mar 12, 7:53AM CDT
BALTIMORE, MD / ACCESSWIRE / March 12, 2015 / Cancer immunotherapy has become today's word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. In this article, I will explain to investors how Cel-Sci Corp. (NYSE MKT:CVM) with its top drug, Multikine, now in Phase III studies for head and neck cancer, deserves to command a much higher share price than currently afforded.
ABT: 36.90 (-1.01), NWBO: 0.59 (-0.04), ZIOP: 5.21 (-0.43), PCYC: 261.25 (+1.70), CVM: 0.46 (unch), PFE: 33.69 (-0.28), CLDX: 4.17 (-0.19), IMGN: 3.01 (-0.12), BMY: 70.82 (+0.21), RIGL: 2.16 (-0.15), INO: 8.53 (-0.64), KITE: 49.62 (-1.12), LH: 127.93 (-1.69), ABBV: 58.81 (-1.05), PBYI: 28.90 (-1.72)